PTC Therapeutics (STU:BH3) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BH3 PTC Therapeutics Inc STU:BH3
52 GF Score
Price €68.32
GF Value €31.66
! 9 Warning Signs
View Full Analysis

What is PTC Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

STU:BH3
52GF Score
PTC Therapeutics Inc STU:BH3
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PTC Therapeutics (STU:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €68.32 is trading 115.8% above its estimated GF Value™ of €31.66.

Key valuation signals for STU:BH3:

  • FFO:
  • GF Value™: €31.66 vs. price of €68.32 (115.8% above fair value)
  • GF Score™: 52/100 with 9 warning signs

No single metric tells the full story. See the STU:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PTC Therapeutics Business Description

Other Exchanges PTCT:USA
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
52GF Score

Get the complete analysis for STU:BH3

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.32
Price
€31.66
GF Value